Newly-published preclinical findings for ATXA Therapeutics' NTP42
ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a further preclinical model of...
World Orphan Drug Virtual Conference
Well done to the ATXA Team, who gave a presentation at the World Orphan Drug Virtual Conference on Monday 17th August. They presented on...
Jonathan Langley Appointment
ATXA Therapeutics & PAH Hope are delighted to welcome Jonathan Langley on board as a non-executive director. Jonathan has vast experience...
ATXA Therapeutics looks to raise $30m to secure regulatory approval
https://www.irishtimes.com/business/technology/atxa-therapeutics-looks-to-raise-30m-to-secure-regulatory-approval-1.4314023
Publication of preclinical findings for ATXA Therapeutics' NTP42
ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a preclinical model of pulmonary...
100 Hot Start Ups.
The companies driving Ireland's entrepreneurial edge. ATXA Therapeutics Ltd is delighted to be recognised amongst such a fantastic list...
ATXA & PAH- Hope attend ERS Congress 2019 in Madrid
We’re here at the ERS Congress 2019 where we will be presenting the our preclinical findings of NTP42 for the treatment of PAH. Please...
ATXA attends the ESC Congress 2019 in Paris
We're here! Drop by the Poster Area for the session on "Pulmonary Arterial Hypertension ‑ Treatments" and talk to us about our...
